Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX48 in Advanced/Metastatic Solid Tumors
NCT07473726Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HLX48 in solid tumor, sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Jun 2026; status: recruiting.
02
Drugs
HLX48
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07473726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473726.